Implantica publishes Interim Report Q3, January – September 2021
A BIG STEP FORWARD WITH FDA IN U.S.Significant events in the third quarter of 2021 · Implantica incorporated wholly owned subsidiary in the US, Implantica Inc. · Implantica filed a supplement to the pre-submission for RefluxStop™ with the FDA. · Implantica appointed new Chief Commercial Officer with proven track record in global sales of medical products. The commercial team has been strengthened with several highly experienced sales and marketing professionals. Implantica also strengthened its management team with a new VP Quality & Regulatory Affairs professional with over 20